(Q33772810)

29 July 2017

Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer (English)

1 reference

29 July 2017

1 reference

Gregory T Wolf

1

1 reference

29 July 2017

Willard E Fee

2

1 reference

29 July 2017

Robert W Dolan

3

1 reference

29 July 2017

Jeffrey S Moyer

4

1 reference

29 July 2017

Michael J Kaplan

5

1 reference

29 July 2017

Paul M Spring

6

1 reference

29 July 2017

James Suen

7

1 reference

29 July 2017

Daniel E Kenady

8

1 reference

29 July 2017

Jason G Newman

9

1 reference

29 July 2017

William R Carroll

10

1 reference

29 July 2017

M Boyd Gillespie

11

1 reference

29 July 2017

Scott M Freeman

12

1 reference

29 July 2017

Lorraine Baltzer

13

1 reference

29 July 2017

Terry D Kirkley

14

1 reference

29 July 2017

Harvey J Brandwein

15

1 reference

29 July 2017

John W Hadden

16

1 reference

29 July 2017

language of work or name

1 reference

31 January 2011

1 reference

29 July 2017

1 reference

29 July 2017

33

1 reference

29 July 2017

12

1 reference

29 July 2017

1666-1674

1 reference

A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Immunotherapy of head and neck cancer: current and future considerations

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Head and neck cancer immunotherapy: clinical evaluation

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

4 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Immunobiology of head and neck cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Global cancer statistics, 2002

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Reprogramming of the immune system during zinc deficiency

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

Alterations in T-lymphocyte subpopulations in patients with head and neck cancer. Correlations with prognosis.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4062188

4 July 2018

1 reference

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

Crossref

Antidepressants, prostaglandins and the prevention and treatment of cancer.

21 January 2018

1 reference

Crossref

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

21 January 2018

1 reference

Crossref

Immunotherapy for head and neck cancer

21 January 2018

1 reference

12 December 2020

Prognostic significance of sinus histiocytosis in metastatic laryngeal cancer

1 reference

12 December 2020

Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer

1 reference

12 December 2020

IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro

1 reference

12 December 2020

Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice

1 reference

12 December 2020

Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma

1 reference

12 December 2020

Nutritional and zinc status of head and neck cancer patients: an interpretive review

1 reference

12 December 2020

Multi-cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose

1 reference

12 December 2020

Identifiers

DOI

10.1002/HED.21660

1 reference

29 July 2017

1 reference

29 July 2017

1 reference